Argenx announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, approved Vyvgart for intravenous use in adults with primary immune thrombocytopenia, or ITP.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
- Rocheâs mixed myasthenia gravis data sending these stocks in opposite directions
- Immunovant rallies after Chugai myasthenia gravis study failure
- Argenx rallies after Chugai generalized myasthenia gravis study fails
- Argenx Highlights 2023 Achievements and Outlook
